Financial Data and Key Metrics Changes - Core revenue for Q3 year-to-date was almost JPY3.1 trillion, reflecting a growth of 4.5% at constant exchange rates [3][24] - Reported revenue growth was 13.9%, with core operating profit growing 9.7% at constant exchange rates to JPY954.7 billion, resulting in a core operating profit margin of 31.1%, an increase of 1.5 percentage points year-over-year [22][24] - Core EPS growth was 17.1% at constant exchange rates, with actual core revenue growth close to 20% and core EPS growth of 37% due to favorable foreign exchange [24][27] Business Line Data and Key Metrics Changes - Growth and Launch products generated approximately JPY1.2 trillion, representing 39% of total revenue and growing at 20% year-to-date at constant exchange rates [25][47] - Neuroscience segment grew by 10%, driven by VYVANSE and TRINTELLIX, while the other segment declined due to regional loss of exclusivities in Japan and low market demand for COVID-19 vaccines [26][88] - PDT Immunology showed strong growth of 18%, including 19% growth in immunoglobulin and 20% growth in albumin, reflecting strong demand [50] Market Data and Key Metrics Changes - The U.S. filing for QDENGA received priority review, and LIVTENCITY showed durable antiviral efficacy in hematopoietic stem cell transplant patients [13][14] - The market for NUVAXOVID in Japan is experiencing lower demand than expected due to the current vaccination situation and prevalence of Omicron [26] Company Strategy and Development Direction - The company aims to create a diverse, equitable, and inclusive working environment, which has been critical in maintaining and developing talent [8] - Strategic investments are being made in long-term growth, including the acquisition of TYK2 inhibitors from Nimbus Therapeutics, which aligns with the company's strategy [10][37] - The company is focused on delivering sustainable growth and value to shareholders, with strong momentum from its commercial portfolio [29] Management's Comments on Operating Environment and Future Outlook - Management is tracking towards the high end of guidance for low single-digit core revenue growth and high single-digit core operating profit and core EPS growth on a constant exchange rate basis [9][23] - The company remains optimistic about its growth outlook, driven by the performance of its Growth and Launch products despite the loss of exclusivity for VELCADE [11][29] Other Important Information - The net debt balance improved from 2.8x to 2.5x, indicating steady deleveraging progress [27][69] - The company plans to maintain its capital allocation policy focused on investing for growth while ensuring competitive shareholder returns [66][69] Q&A Session All Questions and Answers Question: Gross profit margins on a quarter-to-quarter basis - Management noted that gross profit margin improved year-to-date, with a 0.5% increase on an actual basis and 0.1% on a constant exchange basis [56] Question: Market dynamics and pricing for PDT business - Management indicated that PDT growth is driven by volume and demand rather than price, with a slight reduction in donor compensation [90] Question: Concerns about achieving full-year core profit forecast - Management expressed confidence in achieving the full-year forecast of JPY1.18 trillion core operating profit, despite higher R&D and SG&A expenses in Q3 [81][82] Question: Expectations for dividend increases - Management stated that while there is a heightened expectation for increased dividends, they are focused on maintaining their capital allocation policy and will consider updates in the future [82]

41st Annual J.P. Morgan Healthcare Conference Christophe Weber President & CEO January 9th, 2023 Important Notice The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful ...

| --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------| | | | | | | TSE: 4502 | | | | | | | | | | | | | | | | | | | | Better health for people, Brighter future for the world | | | | | | | | | | FY2022 Q2 Earnings Announcement October 27 th , 2022 | | | | IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by ...

Table of Contents FORM 6-K Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of November 2022 ________________________________________ TAKEDA PHARMACEUTIC ...

As filed with the Securities and Exchange Commission on June 29, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant's name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under ...

[Notice of Convocation of the 146th Ordinary General Meeting of Shareholders](index=1&type=section&id=Notice%20of%20Convocation%20of%20the%20146th%20Ordinary%20General%20Meeting%20of%20Shareholders) [Meeting Details and Objectives](index=1&type=section&id=Meeting%20Details%20and%20Objectives) Takeda's 146th Ordinary General Meeting of Shareholders, scheduled for June 29, 2022, will report on fiscal year 145 and address five key proposals, with attendance limited due to COVID-19 - The **146th Ordinary General Meeting of Shareholders** is scheduled for **June 29, 2022**, at the Imperial Hotel, Osaka[1](index=1&type=chunk)[11](index=11&type=chunk) - Due to COVID-19 precautions, shareholders are encouraged to vote in advance, with in-person attendance restricted to a maximum of **500 shareholders**[1](index=1&type=chunk)[11](index=11&type=chunk) Matters to be Resolved | Proposal Number | Description | | :--- | :--- | | First Proposal | Appropriation of Surplus | | Second Proposal | Partial Amendment to the Articles of Incorporation | | Third Proposal | Election of Eleven (11) Directors who are not Audit and Supervisory Committee Members | | Fourth Proposal | Election of Four (4) Directors who are Audit and Supervisory Committee Members | | Fifth Proposal | Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members | [Guidance on Voting and Participation](index=4&type=section&id=Guidance%20on%20Voting%20and%20Participation) Shareholders can vote in writing or online by June 28, 2022, with electronic votes taking precedence; a live stream and advance question submission are available - The deadline for exercising voting rights, either in writing or via electronic means, is **5:30 p.m. on June 28, 2022**[8](index=8&type=chunk)[9](index=9&type=chunk) - If voting rights are exercised multiple times or through different methods, the last vote cast via electronic means will be considered valid[13](index=13&type=chunk) - A live internet stream of the meeting will be available for shareholders, with advance questions accepted online from **June 8 to June 24, 2022**[27](index=27&type=chunk)[28](index=28&type=chunk)[29](index=29&type=chunk) [Reference Document for the General Meeting of Shareholders](index=12&type=section&id=Reference%20Document%20for%20the%20General%20Meeting%20of%20Shareholders) [First Proposal: Appropriation of Surplus](index=12&type=section&id=First%20Proposal%3A%20Appropriation%20of%20Surplus) The company proposes a **90 JPY** year-end dividend, maintaining a **180 JPY** total annual dividend per share, consistent with its capital allocation and shareholder return policy Proposed Dividend | Dividend Type | Amount per Share (JPY) | Total Amount (billion JPY) | Effective Date | | :--- | :--- | :--- | :--- | | Year-end | 90 | 140.36 | June 30, 2022 | - The total annual dividend is **180 JPY per share**, consistent with the prior fiscal year and the company's established dividend policy[35](index=35&type=chunk)[36](index=36&type=chunk) [Second Proposal: Partial Amendment to the Articles of Incorporation](index=12&type=section&id=Second%20Proposal%3A%20Partial%20Amendment%20to%20the%20Articles%20of%20Incorporation) The company proposes amending its Articles of Incorporation to implement electronic provision of shareholder meeting materials, aligning with the amended Companies Act effective September 1, 2022 - The amendment is proposed to comply with the revised Companies Act, which mandates a system for electronic provision of shareholder meeting materials, effective **September 1, 2022**[37](index=37&type=chunk) - Key changes include establishing a new Article 14 for electronic provision of information and limiting the scope of materials sent in hardcopy to shareholders who specifically request them[40](index=40&type=chunk) [Third Proposal: Election of Eleven (11) Directors who are not Audit and Supervisory Committee Members](index=18&type=section&id=Third%20Proposal%3A%20Election%20of%20Eleven%20%2811%29%20Directors%20who%20are%20not%20Audit%20and%20Supervisory%20Committee%20Members) The company proposes electing **eleven directors** not on the Audit and Supervisory Committee, including eight re-elections and three new candidates, with **seven designated as External Directors** Candidates for Director (not ASC Member) | Candidate Name | Status | Role | | :--- | :--- | :--- | | Christophe Weber | Re-elected | President and CEO | | Masato Iwasaki | Re-elected | Representative Director | | Andrew Plump | Re-elected | President, R&D | | Costa Saroukos | Re-elected | Chief Financial Officer | | Olivier Bohuon | Re-elected | External Director | | Jean-Luc Butel | Re-elected | External Director | | Ian Clark | Re-elected | External Director | | Steven Gillis | Re-elected | External Director | | Masami Iijima | Newly elected | External Director | | John Maraganore | Newly elected | External Director | | Michel Orsinger | Newly elected | External Director | - The proposal includes the election of **seven External Directors** to ensure robust corporate governance and oversight[48](index=48&type=chunk) [Fourth Proposal: Election of Four (4) Directors who are Audit and Supervisory Committee Members](index=46&type=section&id=Fourth%20Proposal%3A%20Election%20of%20Four%20%284%29%20Directors%20who%20are%20Audit%20and%20Supervisory%20Committee%20Members) The company proposes electing **four External Directors** to the Audit and Supervisory Committee, including two re-elections and two new candidates, all designated as Independent Directors Candidates for Director (ASC Member) | Candidate Name | Status | Role | | :--- | :--- | :--- | | Koji Hatsukawa | Re-elected | External Director, Head of ASC | | Emiko Higashi | Re-elected | External Director, ASC Member | | Yoshiaki Fujimori | Newly elected | External Director, ASC Member | | Kimberly A. Reed | Newly elected | External Director, ASC Member | - All **four candidates** for the Audit and Supervisory Committee are External Directors, reinforcing the independence of the committee's oversight function[106](index=106&type=chunk) [Fifth Proposal: Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members](index=58&type=section&id=Fifth%20Proposal%3A%20Payment%20of%20Bonuses%20to%20Directors%20who%20are%20not%20Audit%20and%20Supervisory%20Committee%20Members) The company proposes bonuses up to **500 million JPY** for three non-ASC Directors, based on fiscal year KPI achievement, including Consolidated Revenue and Core Operating Profit - A total bonus amount of up to **500 million JPY** is proposed for **three Directors** (excluding overseas and External Directors) who are not ASC members[127](index=127&type=chunk) - The bonus payment is linked to the achievement of fiscal year key performance indicators such as Consolidated Revenue, 14 Global Brands + New Product Incremental Revenue, and Core Operating Profit[127](index=127&type=chunk) [Business Report](index=60&type=section&id=Business%20Report) [Current State of the Takeda Group](index=60&type=section&id=Current%20State%20of%20the%20Takeda%20Group) Takeda is a global R&D-driven biopharmaceutical company focused on key therapeutic areas, leveraging its pipeline and cash flow for growth, deleveraging, and shareholder returns - Takeda's R&D efforts are concentrated in **four main therapeutic areas**: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI)[130](index=130&type=chunk) - The company's strategy focuses on delivering top-line growth, maintaining competitive margins, and generating strong cash flow to fund R&D, reduce debt, and provide shareholder returns[131](index=131&type=chunk) [Business Performance for Fiscal 2021](index=62&type=section&id=Business%20Performance%20for%20Fiscal%202021) Takeda's FY2021 revenue grew **11.6% to 3,569.0 billion JPY**, driven by core therapeutic areas, but operating profit declined **9.5% to 460.8 billion JPY** due to lower divestiture gains FY2021 Consolidated Financial Results (Billion JPY) | Metric | FY2021 (ended Mar 2022) | FY2020 (ended Mar 2021) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 3,569.0 | 3,197.8 | +11.6% | | Operating profit | 460.8 | 509.3 | -9.5% | | Net profit for the year | 230.2 | 376.2 | -38.8% | - Revenue growth was supported by all core therapeutic areas, particularly Gastroenterology, where **ENTYVIO sales increased 21.5% to 521.8 billion JPY**[135](index=135&type=chunk)[138](index=138&type=chunk) - The decline in operating and net profit was largely due to a significant decrease in 'Other operating income', which included a **228.9 billion JPY divestiture gain** in the prior year[152](index=152&type=chunk)[156](index=156&type=chunk)[160](index=160&type=chunk) FY2021 Underlying Results | Metric | Growth Rate | | :--- | :--- | | Underlying Revenue Growth | +7.4% | | Underlying Core Operating Profit Growth | +5.4% | | Underlying Core EPS Growth | +9.4% | [Activities and Results of Research & Development](index=74&type=section&id=Activities%20and%20Results%20of%20Research%20%26%20Development) Takeda's FY2021 R&D expenses were **526.1 billion JPY**, with key FDA approvals for EXKIVITY and LIVTENCITY, strategic partnerships, but also the discontinuation of the TAK-721 program - R&D expenses for the fiscal year totaled **526.1 billion JPY**[178](index=178&type=chunk) - Key U.S. FDA approvals were secured for **EXKIVITY** (mobocertinib) for NSCLC and **LIVTENCITY** (maribavir) for post-transplant CMV infection[200](index=200&type=chunk)[216](index=216&type=chunk) - The development program for **TAK-721** (budesonide oral suspension) for eosinophilic esophagitis was discontinued after receiving a Complete Response Letter from the FDA[228](index=228&type=chunk) - Takeda expanded R&D capabilities through external collaborations, including exercising its option to acquire GammaDelta Therapeutics to advance its gamma delta T cell therapy platforms[246](index=246&type=chunk) [Issues for the Takeda Group to Address](index=100&type=section&id=Issues%20for%20the%20Takeda%20Group%20to%20Address) Takeda addresses a dynamic pharmaceutical landscape through its 'Patient, People, Planet' philosophy, focusing on innovation, digital transformation, sustainability, and a capital allocation policy prioritizing growth, deleveraging, and **180 JPY** per share dividends - Takeda's strategy is guided by its imperatives: Patient (innovative medicines), People (exceptional employee experience), and Planet (sustainability and environmental leadership)[249](index=249&type=chunk)[250](index=250&type=chunk) - The company leverages data, digital, and AI to enhance clinical trials, manufacturing, and employee experiences[255](index=255&type=chunk) - In response to the Ukraine-Russia conflict, Takeda suspended new investments and promotions in Russia while maintaining essential medicine supply to patients in the region[273](index=273&type=chunk)[274](index=274&type=chunk) - The company's capital allocation policy prioritizes investing in growth drivers, rapid deleveraging (targeting **2x net debt/adjusted EBITDA by FY2023**), and shareholder returns, including an annual dividend of **180 JPY per share**[277](index=277&type=chunk) [Financial Forecast for Fiscal 2022](index=108&type=section&id=Financial%20Forecast%20for%20Fiscal%202022) Takeda forecasts FY2022 reported revenue of **3,690.0 billion JPY** (+3.4% YoY), operating profit of **520.0 billion JPY** (+12.8% YoY), and net profit of **292.0 billion JPY** (+26.9% YoY), driven by growth products FY2022 Full Year Reported Forecast (Billion JPY) | Metric | FY2022 Forecast | Change vs. FY2021 (%) | | :--- | :--- | :--- | | Revenue | 3,690.0 | +3.4% | | Operating profit | 520.0 | +12.8% | | Net profit for the year | 292.0 | +26.9% | | Core Operating Profit | 1,100.0 | +15.2% | - Growth is expected from products like ENTYVIO, TAKHZYRO, and newly launched LIVTENCITY and EXKIVITY, which will offset the impact of VELCADE's loss of exclusivity in the U.S[280](index=280&type=chunk) - The forecast includes approximately **50.0 billion JPY** in revenue from COVID-19 vaccines[289](index=289&type=chunk) [Executives of the Company](index=118&type=section&id=Executives%20of%20the%20Company) As of March 31, 2022, Takeda's Board comprises **16 members** (4 internal, 12 external), with compensation designed to attract global talent and align with long-term value, overseen by an external director-led Compensation Committee - As of **March 31, 2022**, the Board of Directors is composed of **4 internal directors** and **12 external directors**, with an external director chairing the board meetings[298](index=298&type=chunk) Total Director Compensation for FY2021 (million JPY) | Category | Number of People | Total Compensation (million JPY) | Basic Compensation (million JPY) | Bonus (million JPY) | Performance Share Units (million JPY) | Restricted Stock Units (million JPY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Directors (not ASC members) | 12 | 3,010 | 677 | 443 | 1,182 | 708 | | Directors (ASC members) | 5 | 174 | 98 | - | - | 76 | - The Director's Compensation Policy is designed to be competitive in the global market, linking pay to performance through short-term bonuses (based on annual KPIs like revenue and profit) and long-term stock incentives (based on **3-year performance** and share price)[312](index=312&type=chunk)[314](index=314&type=chunk)[330](index=330&type=chunk) - The Compensation Committee, comprised entirely of External Directors, has the authority to make decisions on individual compensation for Internal Directors to ensure appropriateness and transparency[335](index=335&type=chunk)[336](index=336&type=chunk) [Financial Statements](index=148&type=section&id=Financial%20Statements) [Consolidated Financial Statements](index=148&type=section&id=Consolidated%20Financial%20Statements) For FY2021, Takeda's consolidated revenue increased **11.6% to 3,569.0 billion JPY**, but operating profit decreased to **460.8 billion JPY**, and net profit to **230.1 billion JPY** Consolidated Statement of Profit or Loss (billion JPY) | Item | Amount (FY2021, billion JPY) | Amount (FY2020, billion JPY) | | :--- | :--- | :--- | | Revenue | 3,569.006 | 3,197.812 | | Operating profit | 460.844 | 509.269 | | Net profit for the year (attributable to owners) | 230.059 | 376.005 | Consolidated Statement of Financial Position (billion JPY) | Item | As of Mar 31, 2022 (billion JPY) | As of Mar 31, 2021 (billion JPY) | | :--- | :--- | :--- | | Total Assets | 13,178.018 | 12,912.293 | | Total Liabilities | 7,494.495 | 7,735.116 | | Total Equity | 5,683.523 | 5,177.177 | [Unconsolidated Financial Statements](index=154&type=section&id=Unconsolidated%20Financial%20Statements) Takeda's unconsolidated FY2021 net sales increased to **764.3 billion JPY**, with net income rising to **324.5 billion JPY**, and total assets at **9,641.6 billion JPY** Unconsolidated Statement of Operations (billion JPY) | Item | Amount (FY2021, billion JPY) | Amount (FY2020, billion JPY) | | :--- | :--- | :--- | | Net sales | 764.301 | 602.557 | | Operating income | 293.709 | 121.071 | | Net income | 324.450 | 247.513 | Unconsolidated Balance Sheet (billion JPY) | Item | As of Mar 31, 2022 (billion JPY) | As of Mar 31, 2021 (billion JPY) | | :--- | :--- | :--- | | Total Assets | 9,641.648 | 10,856.450 | | Total Liabilities | 5,346.749 | 6,421.561 | | Total Net Assets | 4,294.899 | 4,434.889 | [Audit Reports](index=158&type=section&id=Audit%20Reports) [Independent Auditor's Report](index=158&type=section&id=Independent%20Auditor%27s%20Report) KPMG AZSA LLC issued an unqualified opinion on Takeda's consolidated and unconsolidated financial statements for FY2021, affirming fair presentation under IFRS and Japanese GAAP, respectively - The auditor, KPMG AZSA LLC, opined that the consolidated financial statements present fairly, in all material respects, the financial position and results of operations of the Company and its subsidiaries[393](index=393&type=chunk) - The auditor also opined that the unconsolidated financial statements and supplementary schedules present fairly, in all material respects, the financial position and results of operations in accordance with Japanese GAAP[414](index=414&type=chunk) [Audit Report of the Audit and Supervisory Committee](index=170&type=section&id=Audit%20Report%20of%20the%20Audit%20and%20Supervisory%20Committee) The Audit and Supervisory Committee confirmed the accuracy of the Business Report, found no director misconduct, and deemed KPMG AZSA LLC's audit methods and results for both financial statements reasonable - The Business Report and its supplementary schedules were found to accurately present the status of the Company in accordance with laws, regulations, and the Articles of Incorporation[438](index=438&type=chunk) - No misconduct or material violations of law or the Articles of Incorporation were found with respect to the directors' performance of their duties[438](index=438&type=chunk)[440](index=440&type=chunk) - The committee found the methods and results of the audit by the accounting auditors, KPMG AZSA LLC, to be reasonable for both the unconsolidated and consolidated financial statements[442](index=442&type=chunk)

Better health for people, Brighter future for the world February 3, 2022 FY2021 Q3 EARNINGS ANNOUNCEMENT IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does ...

Financial Data and Key Metrics Changes - Year-to-date underlying revenue growth was 7.1% and reported revenue growth was 11% [9][10] - Reported operating profit was ¥462.5 billion, showing significant growth of 28.9% year-over-year [48] - Core operating profit was ¥757.9 billion, a decline of 2.9% compared to the previous year, mainly due to divestitures and increased R&D investment [49][60] - Reported EPS was ¥154, reflecting a growth of 34.5%, while core EPS was ¥333, with underlying core EPS growth of 9.9% [50][69] Business Line Data and Key Metrics Changes - Gastrointestinal (GI) segment grew by 8%, driven by ENTYVIO, which had sales of ¥395 billion year-to-date and underlying growth of 17% [52][55] - Rare diseases declined by 1%, impacted by the decline in rare hematology [52] - Plasma-derived therapies (PDT) immunology grew by 10% [52] - Oncology grew by 8%, and neuroscience was up 10%, with Vyvanse and Trintellix both posting double-digit growth [52] Market Data and Key Metrics Changes - The 14 global brands generated over ¥1 trillion (approximately $9.3 billion) in revenue year-to-date, with an underlying growth of 12% [54] - The company expects significant revenue growth from global brands in the near to medium term, particularly as it expands into new markets [10][57] Company Strategy and Development Direction - The company is focused on advancing innovative life-transforming medicines in oncology, rare genetic and hematologic diseases, neuroscience, and gastroenterology [12] - Strategic R&D investments are being made in plasma-derived therapies and vaccines, with recent approvals for LIVTENCITY and EXKIVITY [12][23] - The planned acquisition of Adaptate Biotherapeutics is aimed at enhancing the immuno-oncology portfolio [15] - A new global portfolio division is being created to enhance launch capabilities for new therapies [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's long-term growth potential, supported by solid margins and strong cash generation [8][11] - The company is upgrading its full fiscal year 2021 forecast for revenue and core operating profits due to strong third-quarter results [11][67] - Management highlighted the importance of digital evolution and data utilization in driving future growth [16] Other Important Information - The company is actively involved in COVID-19 vaccine development and has partnered with Novavax for the development of TAK-019 [21] - The company has made significant debt prepayments and is on track to reduce net debt to adjusted EBITDA ratio to low 2s by the end of fiscal year 2023 [46][64] Q&A Session Summary Question: Reason for the increase in full-year guidance and cost control - Management noted strong business momentum, particularly from the 14 global brands and additional doses of Spikevax in Japan, contributing to the revenue increase [77] - Cost of goods headwinds were attributed to donor fees and foreign exchange impacts, which affected operating profit [78][79] Question: ENTYVIO market share in Crohn's disease - Management indicated that ENTYVIO remains a strong choice for Crohn's disease treatment, with no expected impact from biosimilars [86] Question: Timing for Phase 1 data disclosure for orexin 861 program - Management stated that timelines for various ongoing activities, including the orexin program, will be shared in the fourth quarter [88] Question: Concerns regarding TAK-003 Dengue vaccine candidate - Management clarified that the delay in guidance for the CHMP advisory decision is due to the complexity of the data submitted, not issues with the data itself [91] Question: SG&A costs and Velcade launch timing - Management confirmed that SG&A expenses have increased due to foreign exchange impacts but are being managed effectively [96] - The expected launch for Velcade is still anticipated in Q4 of fiscal year 2021 [97]

FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2022 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant's name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports u ...